Omeros Corporation (OMER) Obtains Regulatory Approval to Initiate Phase 1 Clinical Trial for Lead Antibody in MASP-2 Program
6/13/2013 9:06:54 AM
More...
|
Omeros Corporation (OMER) Reports Positive Results From OMS824 Positron Emission Tomography Clinical Trial
5/31/2013 9:53:22 AM
More...
|
Omeros Corporation (OMER) Files Clinical Trial Application for Lead Antibody in MASP-2 Program
5/28/2013 10:28:40 AM
More...
|
Omeros Corporation (OMER) Release: Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease
5/23/2013 9:49:59 AM
More...
|
Omeros Corporation (OMER) to Present at Two Upcoming Conferences
5/22/2013 6:16:18 AM
More...
|
Omeros Corporation (OMER) Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
5/14/2013 10:57:15 AM
More...
|
Omeros Corporation (OMER) Announces $16.2 Million Registered Direct Offering of Common Stock
5/10/2013 9:36:48 AM
More...
|
Omeros Corporation (OMER) Reports First Quarter 2013 Financial Results
5/10/2013 7:16:19 AM
More...
|
Omeros Corporation (OMER) Requests Fast Track Designation for OMS824 for the Treatment of Huntington's Disease
5/1/2013 9:51:57 AM
More...
|
Omeros Corporation (OMER) Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
4/30/2013 10:31:31 AM
More...
|
|